Trials / Terminated
TerminatedNCT00693004
Study of PRX-03140 Monotherapy in Subjects With Alzheimer's Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of PRX-03140 as Monotherapy in Subjects With Alzheimer's Disease
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 236 (estimated)
- Sponsor
- Epix Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 50 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
A randomized placebo-controlled study to evaluate the efficacy of PRX-03140 monotherapy in subjects with Alzheimer's disease. The study consists of a 3-month double-blind treatment period and an optional 3-month extension period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PRX-03140 | |
| DRUG | Donepezil | |
| DRUG | Placebo |
Timeline
- Start date
- 2008-05-01
- Primary completion
- 2010-01-01
- First posted
- 2008-06-06
- Last updated
- 2009-07-30
Locations
33 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00693004. Inclusion in this directory is not an endorsement.